Skip to content

Serotonin: all studies

Page 283 of 400: studies 2,821 to 2,830 of 3,999, newest first. Back to the serotonin overview

Research

Amitriptyline Accelerates SERT Binding Recovery in a Rat 3,4-Methylenedioxymethamphetamine (MDMA) Model: In Vivo 4-[18F]-ADAM PET Imaging

International Journal of Molecular Sciences June 24, 2022 Chi-Jung Tsai, Chuang-Hsin Chiu, Yu-Yeh Kuo et al.

Numerous studies have confirmed that 3,4-Methylenedioxymethamphetamine (MDMA) produces long-lasting changes to the density of the serotonin reuptake transporter (SERT). Amitriptyline (AMI) has been shown to exert neuroprotective properties in neuropathologic injury. Here, we used a SERT-specific radionuclide, 4-[18F]-ADAM, to assess the longitudinal alterations in SERT binding and evaluate the...

Heart rate (HR) and heart rate variability (HRV) response to inhaled N, N-dimethyltryptamine (N, N-DMT): A case report

Journal of Psychedelic Studies June 23, 2022 David Wyndham Lawrence 5 citations

Abstract Background N, N-Dimethyltryptamine (N, N-DMT) is a naturally occurring tryptamine-based alkaloid and classic psychedelic. The potent psychoactive properties of N, N-DMT are mediated by serotonin 2A (5-HT2A) receptor agonism. There are limited investigations into the physiologic effects of inhaled N, N-DMT, despite this being one of the most common routes of administration. Heart rate...

The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease

Neurology International June 23, 2022 Islam Mohammad Shehata, Waniyah Masood, Nouran Nemr et al. 41 citations

Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s disease (AD). The efficacy of conventional antidepressants to treat depression in AD is...

Sustained effects of single doses of classical psychedelics in humans.

Neuropsychopharmacology June 21, 2022 Gitte M. Knudsen 56 citations

The serotonergic classical psychedelics include compounds that primarily activate the brain's serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of these compounds are well-known as are their ability to increase the emotional state both in healthy people and in those with neuropsychiatric disorders. In particular psilocybin, the psychoactive...

DOI: 10.1038/s41386-022-01361-x (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Therapeutic treatment Depression treatment +1

Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior

International Journal of Molecular Sciences June 16, 2022 Adam Wojtas, Agnieszka Bysiek, Agnieszka Wawrzczak-Bargieła et al. 110 citations

Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting antidepressants, though their mechanisms and toxicity are still not fully understood. To address this issue, we have examined the effect of a single administration of ketamine and psilocybin on the extracellular levels of neurotransmitters in the rat frontal cortex and reticular nucleus of the thalamus...

DOI: 10.3390/ijms23126713 (opens in new tab) Psilocybin Pharmacology Nmda receptor Glutamate receptor

Preface to the special issue “Psychedelics and Neurochemistry”

Journal of Neurochemistry June 14, 2022 C. Nichols, D. Nichols

Psychedelics are a relatively recent field of research that had not gained much support half a century ago, yet it developed into a much acknowledged, highly relevant field that extends to many people's lives. Psychedelics have demonstrated profound and durable therapeutic potential for the treatment of several psychiatric disorders including depression, anxiety, and substance use disorders,...

Cortical Acetylcholine Levels Correlate With Neurophysiologic Complexity During Subanesthetic Ketamine and Nitrous Oxide Exposure in Rats.

Anesthesia & Analgesia June 1, 2022 Michael A. Brito, Duan Li, Christopher W Fields et al.

Neurophysiologic complexity has been shown to decrease during states characterized by a depressed level of consciousness, such as sleep or anesthesia. Conversely, neurophysiologic complexity is increased during exposure to serotonergic psychedelics or subanesthetic doses of dissociative anesthetics. However, the neurochemical substrates underlying changes in neurophysiologic complexity are...

MDMA-Assisted Therapy for Treatment-Resistant Posttraumatic Stress Disorder (PTSD) – One step further toward a patient-centered treatment pathway

European Psychiatry June 1, 2022 S. Pratas Penedos, M.j. Freire, I. Fonseca et al.

IntroductionPTSD is a chronic, debilitating condition with limited treatment efficacy. Accessing traumatic memories often leads to overwhelming distress, impacting treatment process. Current approved pharmacological treatments have exhibited small to moderate effects when compared with placebo. Evidence suggests 3,4,-methylene-dioxymethamphetamine(MDMA)-assisted psychotherapy as a viable option...

Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow.

Psychopharmacology June 1, 2022 Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al. 22 citations

Stream of thought describes the nature of the mind when it is freely roaming, a mental state that is continuous and highly dynamic as in mind-wandering or free association. Classic serotonergic psychedelics are known to profoundly impact perception, cognition and language, yet their influence on the stream of thought remains largely unexplored. To elucidate the effects of LSD on the stream of...

DOI: 10.1007/s00213-021-06006-3 (opens in new tab) Full text (opens in new tab) LSD Abstract thinking Forward flow Free association +4

The promises and perils of psychedelic pharmacology for psychiatry.

Nature Reviews Drug Discovery June 1, 2022 Tristan D Mcclure-Begley, Bryan L. Roth 195 citations

Psychedelic drugs including psilocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...